Abstract: ［Abstract］ Objective〖HTSS〗〓To compare the efficacy and safety between paclitaxel liposome and gemcitabine respectively combined with cisplatin as a first line treatment for nonsmall cell lung cancer with hepatic metastases.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 95 patients were randomly assigned to receive either paclitaxel liposome or gemcitabine respectively combined with cisplatin. Efficacy and safety between two group were compared.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓There was no significant difference in lung cancer of objective response rate ,disease control rate, progressionfree survival between two groups.But objective response rate was higher in paclitaxel liposome group about hepatic metastases. There was no treatmentrelated death among two groups. Paclitaxel liposome was associated with less thrombocytopenia and gastrointesting toxicity.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Paclitaxel liposome has the same efficacy with gemcitabine, and less adverse reactions.Also paclitaxel liposome maybe more helpful to control hepatic metastases.

Key words: lung neoplasms, hepatic metastases, paclitaxel liposome, gemcitabine